Clinical Trials for CLL at ECHO

Beigene’s CELESTIAL Trial

This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia.  The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination of venetoclax with obinutuzumab.  Some patients progress on first line treatment and require additional treatment. 

This study offers a new agent, sonrotoclax.  Sonrotoclax is a next generation BCL-2 drug.  The older drug is venetoclax.  Next generation drugs are developed to improve response and limit side effects.  Clinical trials are designed to determine if these newer investigational agents work well in actual patients.  Another facet of this trial is to determine if investigational agent works so well that there is no minimal residual disease, then the length of treatment can be shortened.

BELLWAVE-011

The BELLWAVE clinical trial program is a series of studies investigating the drug Nemtabrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Nemtabrutinib is a type of targeted therapy called a BTK (Bruton’s tyrosine kinase) inhibitor. 

The BELLWAVE-011 study is a Phase 3, randomized study to compare Nemtabrutinib versus comparator (Investigator’s choice of Ibrutinib or Acalabrutinib) in participants with untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

For more information on these, or other clinical trials, please contact:  Dr. Susan Johnson, Director of Research sjohnson@echoct.com / 860-886-8362.